Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.

ABSTRACT:

Background

Glioblastoma (GBM) represents nearly one-half of primary brain tumors, and the median survival of patients with GBM is only 14.6 months. Surgery followed by radiation with concomitant temozolomide (TMZ) therapy is currently the standard of care. However, an increasing body of evidence suggests that GBM acquires resistance to TMZ, compromising the effect of the drug. Thus, further exploration into the mechanism underlying this resistance is urgently needed. Studies have demonstrated that TMZ resistance is associated with DNA damage, followed by altered reactive oxygen species (ROS) production in mitochondria. Studies have also showed that Ca²⁺-related transient receptor potential (TRP) channels participate in GBM cell proliferation and metastasis, but the detai

SUBMITTER: Chen H 

PROVIDER: S-EPMC9389719 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature